Trial Profile
Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- 01 Sep 2015 New trial record